Trials / Completed
CompletedNCT03230786
Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
A Double-blind, Placebo-controlled, Randomized Study to Evaluate the Efficacy and Safety of KBP-042 in Patients With Type 2 Diabetes
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 255 (actual)
- Sponsor
- KeyBioscience AG · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicentre, randomized, double-blind, placebo-controlled, parallel-group Phase II trial of twelve weeks of KBP-042 administered as daily s.c. injections in subjects with Type 2 Diabetes Mellitus with inadequate glycaemic control while treated with a stable dose of metformin. The trial is planned to be performed in Czech Republic, Denmark, Moldova, Poland, Romania and United Kingdom
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Daily injection of KBP/placebo for 12 weeks as add-on to metformin | Daily subcutaneous injection |
Timeline
- Start date
- 2017-08-23
- Primary completion
- 2018-07-09
- Completion
- 2018-07-31
- First posted
- 2017-07-26
- Last updated
- 2018-09-11
Locations
30 sites across 6 countries: Czechia, Denmark, Moldova, Poland, Romania, United Kingdom
Source: ClinicalTrials.gov record NCT03230786. Inclusion in this directory is not an endorsement.